DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Information Disclosure Statement
The information disclosure statement filed 19 March, 2024 fails to comply with 37 CFR 1.98(a)(3)(i) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each reference listed that is not in the English language. The document EP0115473 is in German, with no English language explanation of the relevance of the reference. Thus, it was not considered.
The information disclosure statement filed 19 March, 2024 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. A number of non-patent literature documents cited in this document were not found in the application file. Thus, they were not considered.
Claim Objections
first objection
Claims 20 and 21 objected to because of the following informalities: these claims list sequences, but do not give the appropriate SEQ ID numbers. The MPEP states that "37 CFR 1.821(d) requires the use of the assigned sequence identifier in all instances where the description or claims of a patent application discuss sequences regardless of whether a given sequence is also embedded in the text of the description or claims of an application” (MPEP 2422.03). Appropriate correction is required.
second objection
Claim 23 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Specification
The disclosure is objected to because of the following informalities: the specification gives amino acid sequences without the appropriate SEQ ID numbers, note p5, 1st paragraph and the table starting at the bottom of p26, for example (and many other locations in the spec). The MPEP states that "37 CFR 1.821(d) requires the use of the assigned sequence identifier in all instances where the description or claims of a patent application discuss sequences regardless of whether a given sequence is also embedded in the text of the description or claims of an application” (MPEP 2422.03).
Appropriate correction is required.
Election/Restrictions
Applicant’s election without traverse of group I and the compound of claim 23 in the reply filed on 14 Sept, 2026 is acknowledged.
The requirement is deemed proper and is therefore made FINAL.
Applicants have elected the compound of claim 23. A search was conducted for this invention, and it was determined to be both novel and unobvious over the prior art. The closest prior art found is Scholte et al (US 2019025514). This reference discusses small peptide sequences labeled with fatty acids for inhibiting proteases in Dengue virus infections, with some sequences with some identity with the elected sequence (note the table of example 3, paragraph 254). However, there is no motivation in either this reference, or any other reference found, to modify those sequences to reconstruct applicant’s elected species. Thus, this embodiment is both novel and unobvious over the prior art.
Following Markush practice, the search was extended to the Markush claim, claim 21, and references were found that rendered obvious at least one embodiment of that claim. As a result, claims 1, 2, 4-7, 9-11, 13, 14, 16, 17, 20, 21, and 23 were examined and claims 3, 8, 12, 15, 18, 19, 22, 24, and 25 were withdrawn from consideration. While one or more of these claims may read on subject material that was found allowable, they have not been completely searched, and, as a result, cannot be stated as allowable. This is proper, as MPEP 803.02 states that "the prior art search . . .will not be extended unnecessarily to cover all non-elected species."
Claims Status
Claims 1-25 are pending.
Claims 3, 8, 12, 15, 18, 19, 22, 24, and 25 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention or species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 14 Sept, 2026.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1, 2, 9-11, 13, 14, 16, 17, and 20 rejected under 35 U.S.C. 101 because they read on a judicial exception (natural phenomenon).
The Supreme Court has given a 2 part test for eligibility under this statute:
1) Is the claim drawn to a process, machine, manufacture, or composition of matter?
2a) If the first test is passed, does a judicial exception apply?
2b) If a judicial exception applies, is there anything beyond the judicial exception?
Applying the test:
The claims are drawn to peptides, a composition of matter, passing the first test.
2a) The Uniprot entry Q694X4 (last updated 2025) describes a regulatory protein from Xanthomonas perforans with a sequence GVANRIEAYR LARQKGWL. Note that positions 12-15 are the sequence ARQK, which reads on the rejected claims. Note that in IAss’n for Molecular Pathology v. Myriad Genetics (569 U S 576), the Supreme Court stated that a naturally occurring segment of DNA, even excised from the chromosome, is a natural product under this judicial exception. This is interpreted that a fragment of a naturally occurring biomolecule is still a naturally occurring compound for purposes of this statute.
2b) The naturally occurring sequence comprises a sequence that reads on the claims. There is no evidence of record that extending the sequence will have any effect on the binding of the sequence to relevant structures. Thus, the claims lack written description.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1, 2, 4-7, 9-11, 13, 14, 16, 17, 20, and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1, and claims dependent on it, allow the “head” portion of the sequence to have a carbonyl or not have a carbonyl. The issue is it is not clear what the AAn comprises – if it has a carbonyl group or not. For example, if head is -C(O)-NH2, it is not clear if this is an α keto amino acid or not. Another way of putting it, it is not clear if the compound of claim 23 has the head group as -NH2 or -C(O)-NH2.
Improper Markush
Claims 1, 2, 4-7, 9-11, 13, 14, 16, 17, 20, and 21 are rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117.
The Markush grouping of the rejected claims is improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons: the claims give no common structural elements that can reasonably be the basis for the activity of the sequences. Even claims with sequences, such as claim 20, have no real identity between all the sequences.
To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1, 2, 5, 6, 9, 13, 14, 16, 17, and 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Scholte et al (US 2019025514).
Scholte et al describe lipopeptides (abstract) which are chemically surfactants (paragraph 248) as protease inhibitors for viral infections (paragraph 1). Among the sequences described, synthesized, and used in a full set of testing is C16-ARQK-C16. This sequence as m=3, link=C(O), tail=C16 alkyl, head=-C(O)-C16 alkyl, anticipating claims 1, 2, 5, and 6. AA1 is Ala, and AAn is Arg-Gln-Lys, anticipating claims 13, 14, 16, 17, and 20.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
first rejection
Claim(s) 1, 2, 4-7, 9, 13, 14, 16, 17, and 20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Scholte et al (US 2019025514).
Scholte et al describe lipopeptides (abstract) which are chemically surfactants (paragraph 248) as protease inhibitors for viral infections (paragraph 1). Among the sequences described, synthesized, and used in a full set of testing is C16-ARQK-C16.
As noted above, this reference anticipates claims 1, 2, 5, 6, 9, 13, 14, 16, 17, and 20.
The difference between this reference and the remaining claims is that the tail is slightly longer.
However, small differences in the lengths of a repeating unit, in this case methylene groups, is not considered a patentable distinction unless the difference makes a significant difference in properties (MPEP 2144.09).
second rejection
Claim(s) 1, 2, 4-7, 9-11, 13, 14, 16, 17, 20, and 21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Scholte et al (US 2019025514) in view of Hirsch (Ultrus sales literature (May 2021)).
Scholte et al describe lipopeptides (abstract) which are chemically surfactants (paragraph 248) as protease inhibitors for viral infections (paragraph 1). Among the sequences described, synthesized, and used in a full set of testing is C16-ARQK-C16. As this is one of the few sequences that have gone through the full range of testing, it is clearly one that the authors are interested in, making it a candidate for further modification. As noted above, this reference anticipates or renders obvious claims 1, 2, 4-7, 9, 13, 14, 16, 17, and 20.
The difference between this reference and the remaining claims is that this reference has one more hydrocarbon tail than the remaining claims.
Hirsch discusses surfactants (title). These compounds have hydrophilic heads and hydrophobic tails (2nd page, 2nd paragraph), and can have one or more hydrophobic tails (figure on p2). This reference discusses surfactants.
Therefore, it would be obvious to remove one of the fatty acid tails of Scholte et al, as a substitution of one known element (the single tail geometry of Hirsch) for another (the double tail geometry of Scholte et al) yielding expected results (surfactants). As Scholte et al refer to these compounds as surfactants, an artisan in this field would attempt this modification with a reasonable expectation of success.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
first rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. 6,329,379. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
second rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. 6,329,417. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
third rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. 6,420,380. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
fourth rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. 6,410,531. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
fifth rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. 6,534,523. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
sixth rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. RE40525. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
seventh rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. RE47894. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
eighth rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. RE41356. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
ninth rejection
Claims 1, 4-7, and 9-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of U.S. Patent No. RE42164. Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims render obvious the examined claims.
Competing claim 1 describes a tripeptide with some sort of hydrophobic tail group. Competing claim 4 limits the tail to acyl groups, including a C1-10 alkyl optionally substituted with a C1-6 alkyl (i.e. C1-16 alkyl). While the competing claims have an acid group at the C-terminus, amides are common in such applications, and are an obvious variant.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to FRED REYNOLDS whose telephone number is (571)270-7214. The examiner can normally be reached M-Th 9-3:30.
Examiner interviews are available via telephone and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/FRED H REYNOLDS/Primary Examiner, Art Unit 1658